Gina L. C. Yosten and Grant R. Kolar
This invention is a humanized antibody or combination of antibodies directed against one or more extracellular domains of the proinsulin C-peptide, GPR146. These antibodies may serve as a C-peptide sensitizer, enhancing C-peptide signaling and activity. This could forestall or reverse diabetes-associated microvascular dysfunction, which can lead to blindness, kidney disease, in loss of feeling or function in the limbs and lead to amputation.
Intellectual Property Status
- U.S. patent pending